2020-2021 Drug Updates in Hematologic Malignancies

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Recent advancements in cancer therapeutics have led to novel drug and biologic approvals.
• Managing patients with hematologic malignancies requires up-to-date knowledge of emerging treatments.

Purpose of the Study:

• To review the label indications of drugs and biologics approved for hematologic malignancies between late 2020 and late 2021.
• To provide advanced practitioners with information on mechanisms of action and safety profiles of new therapeutic agents.

Main Methods:

• Review of drug and biologic approvals for hematologic malignancies.
• Discussion of mechanisms of action and safety profiles.
• Focus on therapies approved from late 2020 to late 2021.

Main Results:

• Several new therapeutic agents were approved for hematologic malignancies.
• Chimeric antigen receptor (CAR) T-cell therapies received approvals across multiple hematologic cancers.
• Other approved agents include phosphoinositide 3-kinase (PI3K) inhibitors, anti-CD38 monoclonal antibodies, and novel immunotherapies.

Conclusions:

• Advanced practitioners must stay informed about new approvals to optimize patient care.
• Understanding the specific indications, mechanisms, and safety of these agents is crucial for effective management.
• The reviewed therapies represent significant progress in treating hematologic malignancies.